Correction: This is story has been updated to correctly state the litigation that was referenced by Hyman, Phelps & McNamara's Sara Koblitz. A district court judge in Delaware has ordered Jazz Pharmaceuticals to remove its risk evaluation and mitigation strategy (REMS) distribution patent for the narcolepsy treatment Xyrem (sodium oxybate) from FDA’s Orange Book, agreeing with the Federal Trade Commission that it was an improper listing that impedes competition. The move could hike pressure on FDA to...